These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19323919)

  • 1. Cardiac resynchronization therapy and B-type natriuretic peptide in heart failure.
    Huang DJ
    Chin Med J (Engl); 2009 Mar; 122(6):608-9. PubMed ID: 19323919
    [No Abstract]   [Full Text] [Related]  

  • 2. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
    Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
    Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin.
    Francia P; Salvati A; Balla C; De Paolis P; Pagannone E; Borro M; Gentile G; Simmaco M; De Biase L; Volpe M
    Eur J Heart Fail; 2007 Mar; 9(3):306-9. PubMed ID: 16891152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months.
    Kubánek M; Málek I; Bytesník J; Frídl P; Riedlbauchová L; Karasová L; Lánská V; Kautzner J
    Eur J Heart Fail; 2006 Dec; 8(8):832-40. PubMed ID: 16546444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
    Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
    Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
    Green SM; Green JA; Januzzi JL
    Am J Ther; 2009; 16(2):171-7. PubMed ID: 19300043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial measurements of plasma B-type natriuretic peptides: what do they tell us?
    Richards AM
    J Am Coll Cardiol; 2008 Sep; 52(12):1004-5. PubMed ID: 18786481
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiac resynchronization therapy modifies the neurohormonal profile, hemodynamic and functional capacity in heart failure patients.
    Menardi E; Vado A; Rossetti G; Racca E; Conte E; Deorsola A; Bobbio M; Feola M
    Arch Med Res; 2008 Oct; 39(7):702-8. PubMed ID: 18760200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved symptoms, physical limitation, and self-efficacy after resynchronization in a patient with heart failure and a prolonged QRS duration.
    Conaway DG; Sullivan R; McCullough PA
    Rev Cardiovasc Med; 2004; 5(1):53-7. PubMed ID: 15029112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy.
    Aarones M; Gullestad L; Aakhus S; Ueland T; Skaardal R; Aass H; Wergeland R; Smith HJ; Aukrust P; Kongsgaard E
    Am Heart J; 2011 Jun; 161(6):1031-7. PubMed ID: 21641347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-type natriuretic peptide as a marker of heart failure: Not so specific after all?
    Marshall W; Orlando R
    Crit Care Med; 2006 Aug; 34(8):2249. PubMed ID: 16883197
    [No Abstract]   [Full Text] [Related]  

  • 13. Improving risk stratification for heart failure. A role for serial testing of B-type natriuretic peptides?
    Daly MG; Frampton CM; Troughton RW
    J Am Coll Cardiol; 2010 Feb; 55(5):451-3. PubMed ID: 20117458
    [No Abstract]   [Full Text] [Related]  

  • 14. Can B-type natriuretic peptides replace heart failure risk models?
    Levy WC
    Eur J Heart Fail; 2008 Mar; 10(3):224-5. PubMed ID: 18313983
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing prognosis in heart failure: you can see a lot if you look, but more if you look again.
    Squire I
    Eur Heart J; 2008 Apr; 29(8):959-60. PubMed ID: 18349028
    [No Abstract]   [Full Text] [Related]  

  • 16. Brain natriuretic peptide is unchanged after 4 weeks of continuous positive airway pressure therapy.
    Pepperell J; Stradling J; Davies R
    J Sleep Res; 2006 Dec; 15(4):463-4. PubMed ID: 17118104
    [No Abstract]   [Full Text] [Related]  

  • 17. Can natriuretic peptides help identify heart failure patients for whom statins are beneficial?
    Daniels LB; Barrett-Connor E
    J Am Coll Cardiol; 2009 Nov; 54(20):1860-1. PubMed ID: 19892236
    [No Abstract]   [Full Text] [Related]  

  • 18. Natriuretic peptide-guided therapy for heart failure: ready for "battle" or too "scarred" by the challenges of trial design?
    Maisel A
    J Am Coll Cardiol; 2009 Dec; 55(1):61-4. PubMed ID: 20117365
    [No Abstract]   [Full Text] [Related]  

  • 19. Natriuretic peptides in heart failure: their role in daily practice.
    Loboz-Grudzień K; Jaroch J
    Cardiol J; 2009; 16(1):1-3. PubMed ID: 19130409
    [No Abstract]   [Full Text] [Related]  

  • 20. Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure.
    Januzzi JL; Bayes-Genis A
    Drug News Perspect; 2009 Jun; 22(5):267-73. PubMed ID: 19609464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.